Status:
COMPLETED
Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Post-Traumatic Stress Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.
Eligibility Criteria
Inclusion
- Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms of PTSD for a minimum of 12 months prior to giving consent to the study
Exclusion
- History of psychotic condition / quetiapine or other anti-psychotics not worked previously / Taking prohibited medications (mood stabilizers / substance abuse)
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00306540
Start Date
December 1 2004
End Date
August 1 2008
Last Update
December 9 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brisbane, Queensland, Australia
2
Research Site
Adelaide, South Australia, Australia
3
Research Site
Melbourne, Victoria, Australia